Skip to Main Content

Paper Details

Risk of Malignancy with Vedolizumab Versus Tumor Necrosis Factor-α Antagonists in Patients with Inflammatory Bowel Diseases.
Dig Dis Sci
2
2022
Author NameAffiliation
Siddharth SinghUniversity of California San Diego, 9452 Medical Center Drive
Siddharth SinghUniversity of California San Diego
Nilay D ShahRobert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic
Nilay D ShahDepartment of Health Services Research, Mayo Clinic
William J SandbornUniversity of California San Diego, 9452 Medical Center Drive
  • 1 - 5

Datasets